The incidence of cardiovascular adverse events (CVAEs), defined as myocarditis, pericarditis, new advanced conduction disease (second- or third- degree heart block), new early conduction abnormality on electrocardiogram (ECG), new asymptomatic rise in Brain Natriuretic Peptide (BNP) or N-Terminal pro BNP, new onset Left Ventricle Systolic Dysfunction, between the Sintilimab group compared with the Pembrolizumab group was 26.0% (15/53) versus 40.0% (8/20) (P=0.26). Here, NPPB is linked to myocarditis.